These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 2495318

  • 1. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
    Yasuda T, Gold HK, Fallon JT, Leinbach RC, Garabedian HD, Guerrero JL, Collen D.
    J Am Coll Cardiol; 1989 May; 13(6):1409-14. PubMed ID: 2495318
    [Abstract] [Full Text] [Related]

  • 2. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA, Gold HK, Yasuda T, Kanke M, Guerrero JL, Fallon JT, Saito T, Collen D.
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [Abstract] [Full Text] [Related]

  • 3. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 4. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis.
    Martin U, Sponer G, Strein K.
    J Am Coll Cardiol; 1992 Feb; 19(2):433-40. PubMed ID: 1732372
    [Abstract] [Full Text] [Related]

  • 6. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
    Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT.
    Circulation; 1988 Mar; 77(3):678-84. PubMed ID: 3124975
    [Abstract] [Full Text] [Related]

  • 7. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA, Anderson RD, MacCord CS, Scott H, Serebruany V, Herzog WR.
    Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
    [Abstract] [Full Text] [Related]

  • 8. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP.
    Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
    [Abstract] [Full Text] [Related]

  • 9. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.
    Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D.
    Circulation; 1988 Mar; 77(3):670-7. PubMed ID: 3124974
    [Abstract] [Full Text] [Related]

  • 10. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
    Söhngen W, Mickelson JK, Simpson PJ, Lucchesi BR.
    Thromb Res; 1988 Jul 01; 51(1):63-74. PubMed ID: 3137691
    [Abstract] [Full Text] [Related]

  • 11. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model.
    Mickelson JK, Simpson PJ, Cronin M, Homeister JW, Laywell E, Kitzen J, Lucchesi BR.
    Circulation; 1990 Feb 01; 81(2):617-27. PubMed ID: 2105175
    [Abstract] [Full Text] [Related]

  • 12. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
    Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR.
    J Cardiovasc Pharmacol; 1994 Feb 01; 23(2):203-11. PubMed ID: 7511748
    [Abstract] [Full Text] [Related]

  • 13. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
    Golino P, Ashton JH, McNatt J, Glas-Greenwalt P, Yao SK, O'Brien RA, Buja LM, Willerson JT.
    Circulation; 1989 Apr 01; 79(4):911-9. PubMed ID: 2494005
    [Abstract] [Full Text] [Related]

  • 14. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.
    Yasuda T, Gold HK, Fallon JT, Leinbach RC, Guerrero JL, Scudder LE, Kanke M, Shealy D, Ross MJ, Collen D, Coller BS.
    J Clin Invest; 1988 Apr 01; 81(4):1284-91. PubMed ID: 2832448
    [Abstract] [Full Text] [Related]

  • 15. Heparin requirement in tissue-type plasminogen activator-induced experimental coronary thrombolysis: comparison with urokinase-induced coronary thrombolysis.
    Susawa T, Yui Y, Hattori R, Takahashi M, Aoyama T, Takatsu Y, Sakaguchi K, Yui N, Kawai C.
    Jpn Circ J; 1987 Apr 01; 51(4):431-5. PubMed ID: 2441082
    [Abstract] [Full Text] [Related]

  • 16. Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator.
    Mehta JL, Nichols WW, Saldeen TG, Chandna VK, Nicolini FA, Lawson DL, ter Riet MF.
    J Cardiovasc Pharmacol; 1990 Jul 01; 16(1):112-20. PubMed ID: 1696653
    [Abstract] [Full Text] [Related]

  • 17. Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Khan S, Mehta JL.
    Am Heart J; 1992 Aug 01; 124(2):280-8. PubMed ID: 1322029
    [Abstract] [Full Text] [Related]

  • 18. Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.
    Saitoh S, Saito T, Otake A, Owada T, Mitsugi M, Hashimoto H, Maruyama Y.
    Arterioscler Thromb; 1993 Apr 01; 13(4):563-70. PubMed ID: 8385480
    [Abstract] [Full Text] [Related]

  • 19. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY, Nichols WW, Mattsson C, Teger-Nilson AC, Wallin R, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1995 Dec 01; 30(6):866-74. PubMed ID: 8746200
    [Abstract] [Full Text] [Related]

  • 20. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR, Wu Z, Pauwels P, Lijnen HR, Collen D.
    J Am Coll Cardiol; 1992 May 01; 19(6):1350-9. PubMed ID: 1342779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.